Order Article Reprints

Dong Y, Zhu Y, Zhuo M, Chen X, Xie Y, Duan J, Bai H, Hao S, Yu Z, Yi Y, et al. Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. Cancers. 2022; 14(22):5649. https://doi.org/10.3390/cancers14225649

Dong, Yiting, Yixiang Zhu, Minglei Zhuo, Xiaomin Chen, Yinpeng Xie, Jianchun Duan, Hua Bai, Shiguang Hao, Zicheng Yu, Yuting Yi, and et al. 2022. "Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer" Cancers 14, no. 22: 5649. https://doi.org/10.3390/cancers14225649

Dong, Y., Zhu, Y., Zhuo, M., Chen, X., Xie, Y., Duan, J., Bai, H., Hao, S., Yu, Z., Yi, Y., Guan, Y., Yuan, J., Xia, X., Yi, X., Wang, J., & Wang, Z. (2022). Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. Cancers, 14(22), 5649. https://doi.org/10.3390/cancers14225649